Research
The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. Researchers from the Centre for Genomic Regulation and the Institute for Research in Biomedicine, both in Barcelona, and the German Cancer Research […]
read more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide
World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]
read more
EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research
More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]
read more
Affimed Announces Filing for the Opening of Insolvency Proceedings
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]
read more
NMI expertise for new VDI guideline on bioprinting – now available
VDI Guideline 5708 “Bioprinting, methods and definitions”: What sounds technical and sober at first glance is an important step forward in the future field of 3D bioprinting. The guideline was developed under the leadership of Dr. Hanna Hartmann from the NMI Natural and Medical Sciences Institute in Reutlingen as chairwoman and Prof. Dr. Jürgen Groll […]
read more
Hella Bühler Prize – Award for Outstanding Contributions to Cancer Research
Dr Dr Varun Venkataramani and Dr Moritz Mall share the 100,000-euro Hella Bühler Prize Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young […]
read more
Antitrust hurdle cleared: Important milestone on the way to the Heidelberg-Mannheim hospital network
At the request of Heidelberg University Hospital, the Ministry of Social Affairs, Health and Integration has confirmed that the merger of the two university hospitals in Heidelberg and Mannheim is deemed necessary to improve hospital care and that the merger does not conflict with any other competition law regulations. Press release from the Ministry of […]
read more
Childhood brain tumors develop early in highly specialized nerve cells
Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have now published their findings in the journal Nature. They […]
read more
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
The partnership combines VERAXA’s proprietary ADC technology with OmniAb’s antibody discovery technology for novel therapies targeting solid tumors. ZURICH, SWITZERLAND, May 5, 2025 — VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: […]
read more
